profit from every $100 of sales.
$0$100
Rein Therapeutics
$0.55-1.41% today
-59.1% in 1 year
1-year low $0.551-year high $1.88
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Rein Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$49.9 million of profit last year.
SalesProfit
Rein Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Rein Therapeutics | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Rein Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -28 | -15 | -28 | -22 | |
| -27 | -15 | -28 | -22 | |
| -27 | -16 | -63 | -50 | |
| -6.02 | -3.42 | -3.51 | -1.96 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 22 | 106 | 62 | 24 |
| Cash | 5 | 17 | 13 | 3 |
| Total debt | 0 | 0 | 0 | – |
| Total liabilities | 3 | 99 | 53 | 52 |
| 19 | 7 | 9 | -28 | |
| 5 | 5 | 18 | 25 | |
| -117.1% | -174.8% | -236.6% | – | |
| -146.7% | -228.4% | -669.9% | 177.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -25 | -20 | -22 | -19 | |
| – | – | – | – | |
| -25 | -20 | -22 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 2 |
Valuation
- –
- –
- –
- 1.7×
- –
- –
- –
- -40.7%
- -104.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -120.3%
- -82.2%
- -281.0%
- -206.4%
- -122.0%
- –
Growth
- –
- –
- +13.1%
- –
- +54.7%
Financial health
- -0.1×
- 0.00
- 0.0%
- –
- 0.70
- 0.70
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Bottom 1%of 987
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.19 | -0.49 | +61.2% |
| Mar 26, 2026 | -1.09 | -1.09 | +0.0% |
| Nov 14, 2025 | -0.21 | -0.24 | +12.5% |
| Aug 14, 2025 | -0.28 | -0.22 | −27.3% |
| Apr 7, 2025 | -0.26 | -0.14 | −85.7% |
| Dec 31, 2024 | -1.89 | -0.46 | −310.7% |
| Nov 14, 2024 | -0.27 | -0.25 | −8.0% |
| Aug 14, 2024 | -0.45 | -0.25 | −80.0% |
News
Apple cuts employee AI budgets as new CEO looks to rein in costsYahoo Finance · Nov 5, 2026Apple Makes Surprising Move to Rein In AI SpendingYahoo Finance · Nov 5, 2026Trump says DOJ will rein in AI 'if we have to'CNBC · Sep 21, 2026California Gov. Newsom issues executive order to rein in AI 'before it's too late'CNBC · Sep 18, 2026House advances bill to rein in AI data center utility costsCNBC · Sep 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
19No pass
Benjamin Graham
41No pass
Philip Fisher
28No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
18No pass
Terry Smith
11No pass
Questions about Rein Therapeutics
Is Rein Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Rein Therapeutics AI analysis
What does Rein Therapeutics do?
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It is in Medical - Pharmaceuticals.
Does Rein Therapeutics pay a dividend?
No. Rein Therapeutics does not pay a dividend at the moment.
Is Rein Therapeutics stock halal?
Yes. Rein Therapeutics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Rein Therapeutics stock done over the past year?
Down 59.1% over the past twelve months, to $0.55. It traded between $0.55 and $1.88 and is 70.6% below its high.
Who are Rein Therapeutics's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Rein Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.